The Switch Study: Switching from BHI 30 Novolet to BIAsp 30 Flexpen: Clinical Observations from the Netherlands. Treatment Satisfaction when Switching from BHI 30 NovoLet® to BIAsp 30 FlexPen®

Aim An open label non-randomized observational study was performed to observe and investigate the process of switching from premixed human insulin 30/70 (BHI 30) in NovoLet® to biphasic insulin aspart 30/70 (BIAsp 30) in FlexPen® in an outpatient setting; in terms of insulin dose, efficacy, hypoglycemic episodes, quality of life (WHO-5) and treatment satisfaction (ITSQ; Insulin Treatment Satisfaction Questionnaire). Methods Type 2 diabetic patients (aged ≥ 18 yrs) treated with BHI30 in NovoLet® who were switched to BIAsp 30 in FlexPen® were included in an open-labeled, multicenter, non-randomi... Mehr ...